Ipsen And Biomunex Reach Licensing Agreement For MAIT Cell Engager In Immuno-Oncology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2024
0mins
Should l Buy ?
Source: Business Insider
Ipsen and Biomunex Collaboration: Ipsen has entered into an exclusive global licensing agreement with Biomunex for BMX-502, a novel T cell engager targeting cancer cells, specifically engaging MAIT cells to attack the tumor antigen GPC3.
Financial Terms of the Agreement: Biomunex stands to gain up to $610 million from Ipsen, which includes upfront payments and milestones, along with tiered royalties on future sales as Ipsen takes charge of clinical development and commercialization.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
